Pharma Firms Lament Inconsistencies In EU Blood, Tissues & Cells Proposal
Stakeholders have suggested changes to the draft EU regulation on substances of human origin to ensure there is no interference with pharmaceutical regulatory activities. They also want clarity on the regulation of advanced therapies and a clear hierarchy for entities dealing with borderline cases.
You may also be interested in...
A full appraisal by the UK cost watchdog is not the only way to gauge the safety and effectiveness of Evusheld, argues the independent Drug Safety Research Unit in response to the government’s decision not to buy the licensed COVID-19 drug because of insufficient data on protection.
EU regulators have developed a draft good practice guide explaining how stakeholders can make use of the Metadata Catalog of RWD Sources, which is expected to be released in late 2023, to identify appropriate sources for specific research questions.
An updated Q&A on the EU Clinical Trial Regulation distinguishes between patient-facing documents and recruitment material to clarify in which sections of the trial application these should be submitted. It also underlines the main principles to consider for transitioning studies from the Clinical Trials Directive to the CTR.